Technology Transfer Funding Opportunity: SBIR Direct-to-Phase II Award
A new funding opportunity announcement (FOA) is available to move commercially viable diagnostic inventions from NIAID and NIDDK intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications for projects that further develop and commercialize such inventions.
The Direct-to-Phase II grant mechanism allows a small business to move directly into a Phase II-type research and development that tests the functional viability of the prototype according to scientific merits and commercial potential.
Any project that fits within the NIAID and NIDDK mission and relies on the use of any NIAID or NIDDK intramural invention(s) listed in the FOA is eligible for this award. 18 diagnostic inventions are listed, including those for hepatitis, tropical diseases, anthrax, cancer, HIV et al. See FOA: NIAID SBIR – Technology Transfer Direct Phase II (SBIR-TT) (R44) for all the details on eligibility and applying, and see the FAQ page for more information.